Emergency Resuscitation Pathology IC-EM-00671 Intermediate Level

Ring-Enhancing Brain Lesion in Advanced HIV: The Toxoplasmosis vs Lymphoma Pivot

Ring-Enhancing Brain Lesion in Advanced HIV: The Toxoplasmosis vs Lymphoma Pivot - Pathology clinical simulation case. 38-year-old male with advanced HIV...

Age: 38 • Gender: Male • Setting: Emergency Triage

Clinical Presentation & History

38-year-old male with advanced HIV (CD4 42 cells/mm3) off antiretrovirals presents with two weeks of progressive left-sided weakness, headache, and intermittent confusion, found to have a ring-enhancing lesion on non-contrast CT.

Acute Resuscitation Milestones & Priorities

Clinical phases and key interventions encountered in this emergency module:

High-Yield Clinical Pearls

In advanced HIV (CD4 <100), a ring-enhancing brain lesion with positive Toxoplasma IgG is treated empirically with pyrimethamine-sulfadiazine-leucovorin; response at 10-14 days is both therapeutic and diagnostic.
Thallium-201 SPECT (high uptake favors lymphoma) and CSF EBV PCR (highly specific for primary CNS lymphoma) are key non-invasive discriminators when biopsy is deferred.
Lumbar puncture is contraindicated with significant midline shift or deep mass lesion due to herniation risk.
Empiric corticosteroids before diagnostic tissue sampling can mask primary CNS lymphoma histology by inducing apoptosis in lymphoid cells.
ART reinitiation is typically deferred 2 weeks after starting anti-toxoplasma induction to reduce the risk of immune reconstitution inflammatory syndrome.
Stereotactic brain biopsy is reserved for non-responders at day 14, atypical lesions, or thallium SPECT suggestive of lymphoma.
Lifelong suppressive therapy is required until CD4 >200 cells/mm3 sustained for at least 6 months to prevent relapse.

Test Your Clinical Reasoning in Real Time

Step into the active clinician role for this case. Order diagnostic tests, analyze live laboratory panels, and navigate branching clinical decisions with real-time feedback.